ReviewJournal of endocrinological investigation2021
Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.
Review in Journal of endocrinological investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Response to targeted radionuclide therapy with [Frontiers in endocrinology · 2022Pooled it
- Analysis of the clinical characteristics of bone metastases after pheochromocytoma/paraganglioma surgery.Frontiers in endocrinology · 2025Article
- Experimental study on the treatment of norepinephrine transporter-overexpressing pheochromocytomas and paragangliomas: a synthetic lethality strategy combiningFrontiers in oncology · 2025Article
- Bone metastases in pheochromocytomas and paragangliomas: a narrative review of presentation, diagnosis and management.Frontiers in endocrinology · 2025Review
- Intraoperative radiofrequency ablation for unresectable abdominal paraganglioma: a case report.Frontiers in endocrinology · 2024Article
- Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.Endocrine reviews · 2023Article
- Favorable outcome in advanced pheochromocytoma and paraganglioma after hypofractionated intensity modulated radiotherapy.Journal of endocrinological investigation · 2023Article
- Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis.European journal of endocrinology · 2022Review
- Review
- Case report: Partial cystectomy for pheochromocytoma of the urinary bladder: A case report and review of literature.Frontiers in cardiovascular medicine · 2022Article
- An Analysis of Computed Tomography Imaging Features and Predictive Factors for Postoperative Recurrence and Metastasis of Abdominal Paragangliomas.Contrast media & molecular imaging · 2022Article
- Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.Journal of endocrinological investigation · 2022Article
- Article
- Analysis of Telomere Maintenance Related Genes RevealsCancers · 2021Article
- Metastatic Pheochromocytomas and Abdominal Paragangliomas.The Journal of clinical endocrinology and metabolism · 2021Review
- Case Report: Successful Control of Pulmonary Metastatic Pheochromocytoma With Iodine-125 Seed Implantation.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic pheochromocytomas and paragangliomas (PPGLs) occur in about 5-26% of cases and are characterized by a heterogeneous prognosis. Metastases can be synchronous at the initial diagnosis, but they can occur also many years after surgery for the primary tumor. To date, the treatment of patients affected by metastatic PPGLs represents a clinical challenge because of the lack of guidelines.
aimThe aim of this article is to review the available management options and their impact on the outcomes of patients with metastatic PPGLs.
resultsGenerally, treatments are not curative. Surgery, when possible, can be used to reduce hormonal symptoms and cardiovascular morbidity. Chemotherapy plays a role in patients with high burden tumor and rapid disease progression. Tyrosine kinases inhibitors (TKIs) might be considered for their ability to block the angiogenesis and cell growth. Radiation therapy and interventional radiology techniques can help in the management of local metastases to control symptoms and avoid tumor progression. On the other hand, peptide receptor radionuclide therapy (PRRT), using
conclusionsThe choice of the appropriate treatment should be based on multidisciplinary and personalized approach taking into account the rarity and the variability of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.